L-arginine and vitamin D adjunctive therapies in pulmonary tuberculosis: a randomised, double-blind, placebo-controlled trial.

What Was Tested

Researchers studied Vitamin D, K2, Magnesium and Zinc in this randomized controlled trial publication.

Vitamin D (vitD) and L-arginine have important antimycobacterial effects in humans.

Who Took Part

The age groups tagged for this paper are teenagers, young adults, adults, middle-aged adults and older adults, both men and women.

All participants with available endpoints were included in analyses according to the study arm to which they were originally assigned.

Adults with new smear-positive PTB were eligible.

How the Study Was Run

In design terms this was a randomized, double-blind and placebo-controlled study.

Because people in this Vitamin D, K2, Magnesium and Zinc study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Blinding on both sides kept the participants and researchers unaware of who received Vitamin D, K2, Magnesium and Zinc.

A placebo (an inactive look-alike) gave the Vitamin D, K2, Magnesium and Zinc group a baseline to be compared against.

The trial was registered at ClinicalTrials.gov NCT00677339.

What Was Measured

The subject headings attached to it are Arginine, Drug Combinations, Mycobacterium tuberculosis, Nitric Oxide, Tuberculosis, Pulmonary and Vitamin D.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc.

The abstract goes on to report its results in about 7 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2013 (PloS one), a journal based in United States.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.